Literature DB >> 25868598

Intracranial hemodynamic changes in primary Sjögren syndrome: a transcranial Doppler case-control study.

Manuela Morreale1, Ada Francia, Pasquale Marchione, Federica Manuppella, Patrizia Giacomini.   

Abstract

The aim of this case-control study is to evaluate the cerebral hemodynamic parameters in primary Sjögren syndrome patients by means of transcranial Doppler and the possible relationship with neuroimaging structural alteration, immunological markers and subclinical neurological involvement. 87 consecutive treatment-naïve outpatients with primary Sjögren syndrome and 86 age- and sex-matched healthy controls underwent transcranial Doppler for bilateral measurement of mean flow velocities, pulsatility index and systolic-diastolic ratio, brain magnetic resonance imaging, clinical evaluation with neuropsychological test and serological assessment. 28 patients and 4 controls (32 vs. 4 %, p .001) had executive function disorders at neuropsychological tests. Mean pulsatility index and systolic-diastolic ratio were significantly higher in both mean cerebral arteries of the patients than in controls (1.3 ± 0.6 vs. 0.9 ± 0.6, p .01 and 3.4 ± 1.7 vs. 1.6 ± 0.7, p .001, respectively). White matter hyperintensities were present in 21 patients and 18 controls. Only age was significantly associated with WMHs in both groups (p < .0001). The increase in systolic-diastolic ratio significantly correlates with neuropsychological impairment. Anti-SSA autoantibodies positively correlate with impaired systolic-diastolic ratio and with neuropsychiatric symptoms. The correlation between haemodynamic changes and anti-SSA autoantibodies suggests a role for the autoimmune response in determining early cerebral hemodynamic dysfunctions. The functional impairment of the endothelium may play a pivotal role in vasomotor dysfunction before any organic damage. The subsequent structural damage of the arterial wall may be responsible for the increase in resistances in small cerebral arteries and sustained hypoperfusion.

Entities:  

Mesh:

Year:  2015        PMID: 25868598     DOI: 10.1007/s10072-015-2204-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  29 in total

1.  Cerebral white matter lesions in primary Sjögren's syndrome: a controlled study.

Authors:  T Coates; J P Slavotinek; M Rischmueller; D Schultz; C Anderson; M Dellamelva; M R Sage; T P Gordon
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  Clinical manifestations and early diagnosis of Sjögren syndrome.

Authors:  Stuart S Kassan; Haralampos M Moutsopoulos
Journal:  Arch Intern Med       Date:  2004-06-28

4.  Middle cerebral artery resistivity and pulsatility indices in systemic lupus erythematosus: evidence for hyperperfusion.

Authors:  E R Greene; K A Yonan; J M Sharrar; W L Sibbitt; C A Roldan
Journal:  Lupus       Date:  2011-11-29       Impact factor: 2.911

5.  Neurological complications of primary Sjögren's syndrome.

Authors:  C Lafitte; Z Amoura; P Cacoub; P Pradat-Diehl; C Picq; F Salachas; J M Léger; J C Piette; J Y Delattre
Journal:  J Neurol       Date:  2001-07       Impact factor: 4.849

6.  Functional impairment of the arterial wall in primary Sjögren's syndrome: combined action of immunologic and inflammatory factors.

Authors:  Roberto Gerli; Gaetano Vaudo; Elena Bartoloni Bocci; Giuseppe Schillaci; Alessia Alunno; Filippo Luccioli; Raed Hijazi; Elmo Mannarino; Yehuda Shoenfeld
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

7.  Pathogenesis of Sjögren's syndrome: what we know and what we should learn.

Authors:  Athanasios G Tzioufas; Efstathia K Kapsogeorgou; Haralampos M Moutsopoulos
Journal:  J Autoimmun       Date:  2012-02-10       Impact factor: 7.094

8.  Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  M A Sloan; A V Alexandrov; C H Tegeler; M P Spencer; L R Caplan; E Feldmann; L R Wechsler; D W Newell; C R Gomez; V L Babikian; D Lefkowitz; R S Goldman; C Armon; C Y Hsu; D S Goodin
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

9.  Evaluation of cerebral perfusion in patients with neuropsychiatric systemic lupus erythematosus using 123I-IMP SPECT.

Authors:  Atsuko Yoshida; Fumio Shishido; Kazuo Kato; Hiroshi Watanabe; Osamu Seino
Journal:  Ann Nucl Med       Date:  2007-06       Impact factor: 2.668

10.  Cerebral blood flow assessed by brain SPECT with 99mTc-HMPAO utilising the acetazolamide test in systemic lupus erythematosus.

Authors:  P Lass; M Koseda; G Romanowicz; J Mechlińska; Z Banecka; M Góra; M Hebanowski; E Stepień; P Łyczak
Journal:  Nucl Med Rev Cent East Eur       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.